A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan.

Abstract

Corticosteroids and biologics are used to treat moderate-to-severe active pediatric ulcerative colitis (UC); however, it is often difficult to continue administration because of systemic side reactions. Vedolizumab is considered to have few adverse effects due to its mechanism of action and it is expected to be used in children, but the long-term administration of vedolizumab to Japanese pediatric patients with UC has not been reported. We report a case of pediatric moderate active UC with anti-tumor necrosis factor-failure that was successfully treated with vedolizumab in Japan.

• Authors: Aiko Ikeuchi, Toshihiko Kakiuchi, Arisa Ibi, Muneaki Matsuo
• Journal: Clinical journal of gastroenterology (Clin J Gastroenterol) Vol. 14 Issue 1 Pg. 146-151 (Feb 2021) ISSN: 1865-7265 [Electronic] Japan
• PMID: 33040281 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Tumor Necrosis Factor-alpha
• vedolizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Child
• Colitis, Ulcerative (drug therapy)
• Humans
• Japan
• Tumor Necrosis Factor-alpha